Interactions of HIV-1 integrase and GAG with nucleic acids, cofactors and inhibitors
Year: 2008
Type: article
Abstract: Acquired immunodeficiency syndrome (AIDS) is one of the greatest health challenges to humans.With current highly active antiretroviral therapy (HAART), the survival of HIV-positive patients has been substantially increased.However, problems associated with the toxicity of currently available drugs and emergence of new infections initiated with HAART-resistant viruses, highlight the need to continually improve available inhibitors and develop new drugs against unexploited targets.Herein, we explored structural features of two key proteins in the HIV life cycle, integrase (IN) and Gag, as antiviral targets in AIDS therapy.In the first part of this research, a novel experimental strategy was established, by combining disulfide meditated IN-DNA cross-linking with mass spectrometric footprinting analysis, for detailed structural analysis of IN-viral DNA interactions.Full length integrase was domain-selectively linked to the respective position on viral DNA substrate.For the first time, N-terminal residue Lys 14 was found be important for viral DNA binding.In addition, we also observed a conformational change involving the connection between the core and C-terminal domains induced by DNA.The importance of the identified contacts for IN activities and virus infection was further confirmed by iii site-directed mutagenesis experiments.These findings enable us to identify the viral DNA binding channel in the active full length IN multimer.We further applied IN-DNA disulfide cross-linking as an in vitro assay to screen potential IN inhibitors binding at the IN catalytic site.We observed a striking difference between two chicoric acid analogs.Acetylated-chicoric acid showed concentrationdependent inhibition on IN-DNA cross-linking, while methyl N,O-bis(3,4diacetoxycinnamoyl) serinate (MDACS) had no effect on it.The only structural difference between these two chicoric acid analogs is at their linker region.Using affinity acetylation and mass spectrometry we previously identified a specific binding site of MDACS at IN the dimer interface.Therefore, we extended our efforts to better understand the structural features of IN inhibitors and determine binding modes.Our results provide structural data for the rational design of future generation of inhibitors with potential clinical relevance.In the second part of this research, HIV-1 Gag was investigated as a potential target for antiviral therapy.We employed mass spectrometric foot-printing to elucidate structural foundations of HIV-1 Gag interactions with its assembly cofactors phosphatidylinositol (4,5) bisphosphate [PI(4,5)P 2 ] and RNA.Of 21 surface exposed lysines in the full length Gag, only two lysines from the matrix domain, K30 and K32, were protected in the Gag: PI(4,5)P 2 complex.In contrast, nucleic acid only protected these two lysines at significant higher concentration, while showing strong protection of lysines K391 and K424, located at the nucleocapsid domain.In addition, a specific iv protection of K314, located in the capsid domain, was observed only in the presence of both PI(4,5)P 2 and nucleic acid.These studies suggested that binding of both cofactors promotes protein-protein interactions involving capsid domain, which must be involved in virus particle assembly.
Author: Zhuojun Zhao
Institution: The Ohio State University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2519812226
